Exploring Adjunctive Novel Therapeutic Approach of KarXT (Xanomeline‐Trospium Chloride) for Managing Psychotic Symptoms in Patients With Schizophrenia and Alzheimer's Disease

Documenti analoghi

• Xanomeline‐Trospium Chloride (Cobenfy): A New Era in Managing Schizophrenia—Comparative Effectiveness and Economic Challenges
  di: Jawairya Muhammad Hussain, et al.
  Pubblicazione: (2025)
• Linking Psychotic‐Like Experiences and Brain White Matter Microstructure in Young Women
  di: Rikka Kjelkenes, et al.
  Pubblicazione: (2025)
• Pharmacotherapy of Psychotic Disorders in Türkiye: Insights From a National Prescription Database
  di: Sena Türkeş, et al.
  Pubblicazione: (2025)
• Role of Probiotics in Management of Depressive Symptoms and Cognitive Impairment in Patients With Depression: An Updated Analysis of Trials
  di: Syed Ali Arsal, et al.
  Pubblicazione: (2025)
• Diagnosis of Schizophrenia and Its Subtypes Using MRI and Machine Learning
  di: Hosna Tavakoli, et al.
  Pubblicazione: (2024)